FORM 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)
[ ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2001
---------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
--------------- -----------------
Commission file number 0-28740
--------------
MIM CORPORATION
---------------------------------
(Exact name of registrant as specified in its charter)
Delaware 05-0489664
- --------------------------------------------------------------------------------
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
100 Clearbrook Road, Elmsford, NY 10523
(Address of principal executive offices)
(914) 460-1600
--------------
(Registrant's telephone number, including area code)
------------------------------------------------------------------------
(Former name, former address and former fiscal year
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS:
On April 24, 2001 there were outstanding 20,419,120 shares of the Company's
common stock, $.0001 par value per share ("Common Stock").
INDEX
PART I FINANCIAL INFORMATION Page Number
- ---------------------------------------------------------------------------------------------------------
Item 1 Financial Statements
Consolidated Balance Sheets at March 31, 2001 (unaudited) 1
and December 31, 2000
Unaudited Consolidated Statements of Income for the three 2
months ended March 31, 2001 and 2000
Unaudited Consolidated Statements of Cash Flows for the 3
three months ended March 31, 2001 and 2000
Notes to the Consolidated Financial Statements 5
Item 2 Management's Discussion and Analysis of Financial Condition 8
and Results of Operations
Item 3 Quantitative and Qualitative Disclosures about Market Risk 12
PART II OTHER INFORMATION
Item 1 Legal Proceedings 13
Item 2 Changes in Securities and Use of Proceeds 13
Item 4 Submission of Matters to a Vote of Security Holders 14
Item 5 Other Information 14
Item 6 Exhibits and Reports on Form 8-K 14
SIGNATURES 15
Exhibit Index 16
ii
1
PART I
FINANCIAL INFORMATION
Item 1. Financial Statements
MIM CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
March 31, December 31,
2001 2000
------------ -----------
ASSETS (Unaudited)
Current assets
Cash and cash equivalents $ 1,114 $ 1,290
Receivables, less allowance for doubtful accounts of $5,741 and $8,333
at March 31, 2001 and December 31, 2000, respectively 62,963 56,809
Inventory 3,908 2,612
Prepaid expenses and other current assets 1,397 1,680
-------------- -------------
Total current assets 69,382 62,391
Property and equipment, net 11,060 10,813
Due from affiliate and officer 2,049 2,012
Other assets, net 2,724 2,163
Intangible assets, net 38,779 39,023
-------------- -------------
Total assets $ 123,994 $ 116,402
============== =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Current portion of capital lease obligations $ 573 $ 592
Current portion of long-term debt 109 165
Accounts payable 3,894 2,964
Claims payable 44,126 35,338
Payables to plan sponsors and others 25,617 29,040
Accrued expenses 5,562 5,476
-------------- -------------
Total current liabilities 79,881 73,575
Capital lease obligations, net of current portion 1,481 1,621
Other non current liabilities 357 589
Minority interest 1,112 1,112
Stockholders' equity
Preferred stock, $.0001 par value; 5,000,000 shares authorized,
250,000 Series A junior participating shares issued and outstanding - -
Common stock, $.0001 par value; 40,000,000 shares authorized,
20,249,129 and 21,547,312 shares issued and outstanding
at March 31, 2001 and December 31, 2000, respectively 2 2
Treasury stock at cost (2,934) (338)
Additional paid-in-capital 97,010 97,010
Accumulated deficit (52,915) (56,398)
Stockholder notes receivable - (771)
-------------- -------------
Total stockholders' equity 41,163 39,505
-------------- -------------
Total liabilities and stockholders' equity $ 123,994 $ 116,402
============== =============
The accompanying notes are an integral part of these consolidated financial
statements.
1
MIM CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)
Three months ended
March 31,
----------------------------------
2001 2000
----------------------------------
(Unaudited)
Revenue $ 106,036 $ 80,517
Cost of revenue 94,400 73,706
--------------- ---------------
Gross profit 11,636 6,811
Selling, general and administrative expenses 8,403 6,239
TennCare reserve adjustment (980) -
Amortization of goodwill and other intangible assets 519 258
--------------- ---------------
Income from operations 3,694 314
Interest income, net 42 411
--------------- ---------------
Income before taxes 3,736 725
Income taxes 253 -
--------------- ---------------
Net income $ 3,483 $ 725
=============== ===============
Basic income per common share $ 0.17 $ 0.04
=============== ===============
Diluted income per common share $ 0.17 $ 0.04
=============== ===============
Weighted average common shares used
in computing basic income per share 20,884 18,753
=============== ===============
Weighted average common shares used
in computing diluted income per share 20,980 19,425
=============== ===============
The accompanying notes are an integral part of these consolidated financial
statements.
2
MIM CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Three Months Ended
-------------------------------
March 31, March 31,
2001 2000
-------------------------------
(Unaudited)
Cash flows from operating activities:
Net income $ 3,483 $ 725
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other 1,416 992
Provision for losses on receivables 305 130
Changes in assets and liabilities:
Receivables (6,459) 5,564
Inventory (1,296) (370)
Prepaid expenses and other current assets 283 (30)
Accounts payable 930 7
Claims payable 8,788 35
Payables to plan sponsors and others (3,423) (957)
Accrued expenses 86 3,641
Other non current liabilities (232) (308)
-------------- ----------------
Net cash provided by operating activities 3,881 9,429
-------------- ----------------
Cash flows from investing activities:
Purchase of property and equipment (1,144) (1,167)
Loans to affiliate and officer, net (37) (144)
Stockholder loans, net - (11)
Cost of acquisition (275) -
Purchase of investment securities - (2,000)
Maturities of investment securities - 1,047
Decrease (increase) in other assets 210 (567)
-------------- ----------------
Net cash used in investing activities $ (1,246) $ (2,842)
-------------- ----------------
Cash flows from financing activities:
Principal payments on capital lease obligations (159) (159)
Repayment of long term debt (56) (1,297)
Exercise of stock options - 240
Purchase of treasury stock (2,596) -
-------------- ----------------
Net cash used in financing activities (2,811) (1,216)
-------------- ----------------
Net (decrease) increase in cash and cash equivalents (176) 5,371
Cash and cash equivalents--beginning of period $ 1,290 $ 15,306
-------------- ----------------
Cash and cash equivalents--end of period $ 1,114 $ 20,677
============== ===============
The accompanying notes are an integral part of these consolidated financial
statements.
3
MIM CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(continued)
(In thousands)
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest $ 60 $ 41
=============== ================
SUPPLEMENTAL DISCLOSURE OF NONCASH INFORMATION:
Reclassification of stockholder notes to other assets $ 771 $ -
=============== ================
4
MIM CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(In thousands, except per share amounts)
NOTE 1 - BASIS OF PRESENTATION
The accompanying unaudited consolidated interim financial statements of MIM
Corporation and its subsidiaries (collectively, the "Company" or "MIM") have
been prepared pursuant to the rules and regulations of the U.S. Securities and
Exchange Commission (the "Commission"). Pursuant to such rules and regulations,
certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. In the opinion of the Company's management, all
adjustments considered necessary for a fair presentation of the financial
statements, primarily consisting of normal recurring adjustments, have been
included. The results of operations and cash flows for the three months ended
March 31, 2001, are not necessarily indicative of the results of operations or
cash flows, which may be reported for the remainder of 2001.
These unaudited consolidated interim financial statements should be read in
conjunction with the Company's audited consolidated financial statements, notes
and information included in the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 2000, filed with the Commission (the "Form
10-K").
The accounting policies followed for interim financial reporting are the
same as those disclosed in Note 2 to the consolidated financial statements
included in the Form 10-K.
NOTE 2 - EARNINGS PER SHARE
The following table sets forth the computation of basic earnings per share
and diluted earnings per share:
Three Months Ended
March 31,
------------------
2001 2000
----- -----
Numerator:
Net income ...................................... $ 3,483 $ 725
Denominator - Basic:
Weighted average number of common
shares outstanding .............................. 20,884 18,753
======= =======
Basic income per share .......................... $ 0.17 $ 0.04
======= =======
Denominator - Diluted:
Weighted average number of common
shares outstanding ........................... 20,884 18,753
Common share equivalents of outstanding
stock options ................................ 96 672
------- -------
Total shares outstanding ........................ 20,980 19,425
======= =======
Diluted income per share ........................ $ 0.17 $ 0.04
======= =======
5
NOTE 3 - RECENT ACCOUNTING PRONOUNCEMENTS
In June 1998, the Financial Accounting Standards Board ("FASB") issued SFAS
No. 133, "Accounting for Derivative Instruments and Hedging Activities" ("SFAS
133"). The statement establishes accounting and reporting standards requiring
that every derivative instrument be recorded in the balance sheet as either an
asset or liability measured at fair value and that changes in fair value be
recognized currently in earnings, unless specific hedge accounting criteria are
met. In June 1999, the FASB issued SFAS No. 137, "Accounting for Derivative
Instruments and Hedging Activities - Deferral of the Effective Date of SFAS No.
133," which delayed the required adoption of SFAS 133 to fiscal 2001. In June
2000, the FASB issued SFAS 138, "Accounting for Certain Derivative Instruments
and Certain Hedging Activities," - an amendment of SFAS 133," which was
effective concurrently with SFAS 133. In January 2001, the Company adopted these
standards. The Company currently does not engage in derivative activity and the
adoption of these standards did not have a material effect on its results of
operations, financial position or cash flows.
In January 2001, the Company adopted Emerging Issues Task Force Issue
No. 00-22 ("EITF 00-22"), "Accounting for `Points' and Certain Other Time-Based
or Volume-Based Sales Incentive Offers, and Offers for Free Products or Services
to Be Delivered in the Future." EITF 00-22, states, among other things, that
rebates billed to pharmaceutical manufacturers should be recognized as a
reduction of revenue. Prior to adoption of EITF 00-22, the Company recorded only
the difference between the rebates billed and the rebates shared with customers
as a reduction of cost of revenue. The adoption of EITF 00-22 required the
Company to classify $7,750 and reclassify $8,587 rebates shared for the three
month periods ended March 31, 2001 and March 31, 2000 respectively as a
reduction of revenue.
NOTE 4 - STOCKHOLDER NOTES RECEIVABLE
As of March 31, 2001, the Company has reclassified stockholder notes
receivable of approximately $771 from a reduction of stockholders equity to
other assets. Although the loans did not originate from the issuance of, or were
otherwise collateralized by, the Company's equity securities, the Company
initially classified the promissory notes in equity due to the nature of the
borrowers' relationship to the Company at the time of the notes' origination. At
that time, the borrowers were affiliated (through common ownership) with an
individual (the "Founder") who was the President and majority stockholder of the
Company. As such, the borrowers and the Company were entities under common
control at the time and the promissory notes were therefore treated as equity.
This shareholder is no longer President or a majority shareholder of the company
and accordingly, the borrowers and the Company are no longer considered to be
entities under common control.
NOTE 5 - TREASURY STOCK
In February 2001, the Company repurchased 1,298,183 shares of the Company's
common stock for $2,596, at a price of $2.00 per share.
NOTE 6 - COMMITMENTS AND CONTINGENCIES
Prior to the settlement of the litigation discussed below, the Company had
disputed several improper reductions of payments by Tennessee Health Partnership
("THP"), a former TennCare(R) managed care organization ("MCO"), to which the
Company previously provided pharmaceutical benefit management ("PBM") services.
In addition, a dispute arose over whether or not certain items should have been
included under the Company's capitated arrangement with THP. In 1999, the
Company recorded a special charge of $2,900 for estimated future losses related
to these disputes.
During the first quarter of 2001, the Company reached an agreement in
principle with THP. The Company paid THP $1,300 in satisfaction of all claims
between the parties and the parties released each other from any and all
liability with respect to past or future claims. The terms of the settlement
were favorable to the Company and $1,000 of excess reserves were credited to
income during the first quarter.
In 1998, the Company recorded a $2,200 special charge against earnings in
connection with an agreement in principle with respect to a civil settlement of
a Federal and State of Tennessee investigation in connection with
6
conduct involving, among others, two former officers of the Company occurring
prior to the Company's August 1996 initial public offering. The definitive
agreement covering that settlement was executed on June 15, 2000, and required
payment of $775 in 2000 and payment of $900 in 2001 and in 2002. $1,200 and
$1,420 was outstanding at March 31, 2001 and December 31, 2000, respectively,
and is included in accrued expenses and other non-current liabilities.
NOTE 7 - RECENT ACQUISITION
On August 4, 2000, the Company acquired all of the issued and outstanding
membership interests of American Disease Management Associates, L.L.C., a
Delaware limited liability company ("ADIMA"). The aggregate purchase price
approximated $24,000, and included $19,000 in cash and 2,700 shares of MIM
common stock valued at $5,000.
The following unaudited consolidated pro forma financial information for
the three months ended March 31, 2001, and March 31, 2000, has been prepared
assuming ADIMA was acquired as of January 1, 2000, with pro forma adjustments
for amortization of goodwill and interest income. The pro forma financial
information is presented for informational purposes only and is not necessarily
indicative of the results that would have been realized had the acquisition
occurred on January 1, 2000. In addition, this pro forma financial information
is not intended to be a projection of future operating results.
Three Months ended March 31,
(In thousands, except per share amounts)
(unaudited)
--------------------------------------------
2001 2000
-------------------- ---------------------
Revenues $ 106,036 $ 84,579
Net income 3,483 1,437
Basic earnings per share 0.17 0.07
Diluted earnings per share 0.17 0.06
EBITDA 5,223 2,504
* * * *
7
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations
The following management's discussion and analysis should be read in
conjunction with the consolidated financial statements of MIM Corporation and
its subsidiaries (collectively, "MIM" or the "Company"), the related notes
thereto and Management's Discussion and Analysis of Financial Condition and
Results of Operations included in the Company's Annual Report on Form 10-K for
the fiscal year ended December 31, 2000 (the "Form 10-K"), as well as the
Company's unaudited consolidated interim financial statements and the related
notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q
for the fiscal quarter ended March 31, 2001, filed with the Commission (this
"Report").
This Report contains statements not purely historical and which may be
considered forward looking statements within the meaning of Section 27A of the
Securities Act, and Section 21E of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), including statements regarding the Company's
expectations, hopes, beliefs, intentions or strategies regarding the future.
Forward looking statements may include statements relating to the Company's
business development activities, sales and marketing efforts, the status of
material contractual arrangements including the negotiation or re-negotiation of
such arrangements, future capital expenditures, the effects of regulation and
competition on the Company's business, future operating performance and the
results, benefits and risks associated with integration of acquired companies,
the likely outcome and the effect of legal proceedings on the Company and its
business and operations and/or the resolution or settlement thereof. Investors
are cautioned that any such forward looking statements are not guarantees of
future performance and involve risks and uncertainties, and that actual results
may differ materially from those possible results discussed in the forward
looking statements as a result of various factors. These factors include, among
other things, risks associated with risk-based or "capitated" contracts,
increased government regulation related to the health care and health insurance
industries in general and more specifically, pharmacy benefit management
organizations, the existence of complex laws and regulations relating to the
Company's business, increased competition from the Company's competitors,
including competitors with greater financial, technical, marketing and other
resources. This Report contains information regarding important factors that
could cause such differences. The Company does not undertake any obligation to
supplement these forward-looking statements to reflect any future events and
circumstances.
Overview
MIM is a pharmacy benefit management ("PBM"), specialty pharmaceutical and
fulfillment organization that partners with healthcare providers and sponsors to
control prescription drug costs. MIM's innovative pharmacy benefit products and
services use clinically sound guidelines to ensure cost control and quality
care. MIM's specialty pharmaceutical division specializes in serving the
chronically ill affected by life threatening diseases and genetic impairments or
after hospital discharge. MIM's fulfillment center provides prescription mail
service specializing in serving individuals that require long-term
maintenance medications. MIM's online pharmacy, www.MIMRx.com, develops private
label websites to offer affinity groups and health care providers innovative,
customized health information services and products on the Internet for their
members.
Business
The Company derives its revenues primarily from agreements to provide PBM
services, which includes prescription mail service to the members of various
health plan sponsors in the United States. The Company also provides specialty
pharmacy services to chronically ill or genetically impaired patients that
require injection and infusion therapies.
A majority of the Company's revenues to date have been derived from
providing PBM services in the State of Tennessee (the "State") to MCO's
participating in the State's TennCare(R) program. At March 31, 2001, the Company
provided PBM services to 130 health plan sponsors with an aggregate of
approximately 5.9 million plan members, of which TennCare(R) represented five
MCO's with approximately 1.1 million plan members. Revenues derived from the
Company's contracts with those TennCare(R) MCO's accounted for 35.3% of the
Company's revenues at March 31, 2001, compared to 54.8% of the Company's
revenues for the three months ended March 31, 2000.
8
Results of Operations
Three months ended March 31, 2001 compared to three months ended March 31, 2000
Revenues for the quarter were up 31.7% to $106.0 million compared with
$80.5 million for the first quarter a year ago. Commercial PBM and mail order
revenues accounted for $17.3 million of the $25.5 million increase, as a result
of an increase in contracted lives. For the three months ended March 31, 2001,
25.2% of the Company's revenues were generated from capitated contracts,
compared to 38.2% for the same period in 2000. Specialty pharmaceutical revenue,
which includes revenues derived from ADIMA, contributed $8.2 million of the
additional revenue during the period as well.
Cost of revenue for the three months ended March 31 was $94.4 million,
compared with $73.7 for the same period in 2000, an increase of $20.7 million.
Cost of revenue increased due to the inclusion of ADIMA's operations and
increases in commercial PBM and mail order costs resulting from increased lives
under management. These increases were partially offset by a decrease in cost of
revenue as a result of additional rebates from prior years that where contracted
for in the first quarter of 2001.
Selling, general and administrative expenses were $8.4 million for the
three-month period ended March 31, 2001, as compared to $6.2 million for the
three months ended March 31, 2000. This increase of $2.2 million was primarily
the result of the consolidation of ADIMA, increased operating expenses due to
the relocation of the mail order facility in 2000, and increased sales and
marketing expenses. As a percentage of revenue, selling, general and
administrative expenses decreased to 7.9% for the three months ended March 31,
2001, from 7.7% for the same period for 2000.
For the three months ended March 31, 2001, the Company recorded amortization
of goodwill and other intangibles of $0.5 million compared to $0.3 million for
the same period in 2000. This increase reflects the inclusion of goodwill
associated with ADIMA.
For the three months ended March 31, 2001, the Company recorded net interest
income of $0.1 million compared to $0.4 million for the three months ended March
31, 2000, a decrease of $0.3 million, primarily due to a decrease in the
Company's cash, which was used to acquire ADIMA, thereby resulting in lower
investments in the first quarter.
For the three months ended March 31, 2001, the Company recorded net income
of $3.5 million or $0.17 per diluted share, including the credit to net income
of $1 million as a result of the THP settlement. This compares with net income
of $0.7 million, or $0.04 per diluted share for the three months ended March 31,
2000.
Earnings before interest, taxes, depreciation and amortization was $5.2
million for the three-month period ended March 31, 2001, and $1.3 million for
the three-month period ended March 31, 2000.
Liquidity and Capital Resources
The Company utilizes both funds generated from operations and funds
available to it under its credit facility for capital expenditures and other
working capital needs. For the three months ended March 31, 2001, net cash
generated by the Company from operations totaled $3.9 million. The decrease was
the result of several factors including increased receivables, increased
inventory, and increased claims payable, which was partially offset by a
decrease in payables to plan sponsors and others. Receivables and claims
payables have increased as a result of higher revenues from increased business.
Inventory rose due to the implementation during the first quarter of 2001 of the
automation system which required a one time increase in inventory to stock the
machinery for its initial startup. Payables to plan sponsors and others reflect
the fulfillment of obligations to the MCO's for prior quarter rebate share
payables.
Net cash used in investing activities was $1.2 million, which was used
primarily for the purchase of property and equipment. This included the final
payment for the automation system at the mail service facility.
For the three months ended March 31, 2001, net cash used in financing
activities was $2.8 million. The repurchase of the Company's shares in a private
transaction was the majority of cash used in financing activities.
9
At March 31, 2001, the Company had a working capital deficit of $10.5
million compared to a working capital deficit of $11.2 million at December 31,
2000.
On November 1, 2000, the Company entered into a $45 million revolving
credit facility (the "Facility") with HFG Healthco-4 LLC, an affiliate of
Healthcare Finance Group, Inc. ("HFG"), to be used for working capital purposes
and future acquisitions. The Facility replaced the Company's existing credit
facilities with its former lenders. The Facility has a three-year term and is
secured by the Company's receivables. Interest is payable monthly and provides
for borrowing up to $45 million at the London Inter-Bank Offered Rate (LIBOR)
plus 2.1%. In connection with the issuance of the Facility, the Company incurred
financing costs of $1.6 million which are included in other assets and are being
amortized over the term of the Facility. The Facility contains various covenants
that, among other things, require the Company to maintain certain financial
ratios, as defined in the agreement governing the Facility.
From time to time, the Company may be a party to legal proceedings or
involved in related investigations, inquiries or discussions, in each case,
arising in the ordinary course of the Company's business. Management does not
presently believe that any current matters would have a material adverse effect
on the liquidity, financial position or results of operations of the Company.
At December 31, 2000, the Company had, for tax purposes, unused net
operating loss carryforwards of approximately $44.2 million, which will begin
expiring in 2009. As it is uncertain whether the Company will realize the full
benefit from these carryforwards, the Company has recorded a valuation allowance
equal to the deferred tax asset generated by the carryforwards. The Company
assesses the need for a valuation allowance at each balance sheet date. The
Company has undergone a "change in control" as defined by the Internal Revenue
Code of 1986, as amended ("Code"), and the rules and regulations promulgated
thereunder. The amount of net operating loss carryforwards that may be utilized
in any given year will be subject to a limitation as a result of this change.
The annual limitation is approximately $2.7 million. Actual utilization in any
year will vary based on the Company's tax position in that year.
As the Company continues to grow, it anticipates that its working capital
needs will also continue to increase. The Company believes that it has
sufficient cash on hand or available credit under the Facility to fund the
Company's anticipated working capital and other cash needs for at least the next
12 months.
The Company also may pursue joint venture arrangements, business
acquisitions and other transactions designed to expand its PBM, fulfillment or
specialty pharmacy businesses, which the Company would expect to fund from cash
on hand, the Facility, other future indebtedness or, if appropriate, the sale or
exchange of equity securities of the Company.
Other Matters
The TennCare(R) program operates under a demonstration waiver from HCFA.
That waiver is the basis of the Company's ongoing service to those MCO's in the
TennCare(R) program. The waiver is due to expire on December 31, 2001. However,
the Company believes that pharmacy benefits will continue to be provided to
Medicaid and other eligible TennCare(R) enrollees through MCO's in one form or
another, although there can be no assurances that such pharmacy benefits will
continue or that the Company would be chosen to continue to provide pharmacy
benefits to enrollees of a successor program. If the waiver is not renewed and
the Company is not providing pharmacy benefits to those lives under a successor
program or arrangement, then the failure to provide such services would have a
material and adverse affect on the financial position and results of operations
of the Company. The ongoing funding for the TennCare(R) program has been the
subject of significant discussion at various governmental levels since its
inception. Should the funding sources for the TennCare(R) program change
significantly, the Company's ability to serve those customers could be impacted
and would also materially and adversely affect the financial position and
results of operations of the Company.
On November 1, 2000, the TennCare(R) program adopted new rules for
recipients to appeal adverse determinations in the delivery of health care
services and products requiring prior approval including the rejections of
certain pharmaceutical products under existing formularies or guidelines and to
possibly receive a larger supply of the rejected products at the point of
service. The implementation of these rules may impact the quantity of
10
formulary products excluded or requiring prior approval that are dispensed to
the recipients potentially resulting in a change to the amount of pharmaceutical
manufacturers rebates earned by the Company. A reduction in rebates would
adversely impact the financial results of the Company. At this time the Company
cannot estimate the financial impact, if any, as a result of the implementation
of new rules.
As a result of providing capitated PBM services to certain TennCare(R)
MCO's, the Company's pharmaceutical claims costs historically have been subject
to significant increases from October through February, which the Company
believes is due to the need for increased medical attention to, and intervention
with, MCO's members during the colder months. The resulting increase in
pharmaceutical costs impacts the profitability of capitated contracts. Capitated
business represented approximately 25.2% of the Company's revenues while fee for
service business (including mail order services and specialty) represented
approximately 69.9% of the Company's revenues for the three months ended March
31, 2001 as compared to 34.5% and 65.5% for the three months ended March 31,
2000, respectively. Fee-for-service arrangements mitigate the adverse effect on
profitability of higher pharmaceutical costs incurred under capitated contracts,
as higher utilization positively impacts profitability under fee-for-service (or
non-capitated) arrangements. The Company presently anticipates that
approximately 20% of its revenues in fiscal 2001 will be derived from capitated
arrangements.
Changes in prices charged by manufacturers and wholesalers or distributors
for pharmaceuticals, a component of pharmaceutical claims costs, directly
affects the Company's cost of revenue. The Company believes that it is likely
that prices will continue to increase, which could have an adverse effect on the
Company's gross profit on capitated arrangements. Because plan sponsors are
billed for the cost of all prescriptions dispensed in fee-for-service
arrangements, the Company's gross profit is not adversely affected by changes in
pharmaceutical prices. To the extent such cost increases adversely affect the
Company's gross profit, the Company may be required to increase capitated
contract rates on new contracts and upon renewal of existing capitated
contracts. However, there can be no assurance that the Company will be
successful in obtaining these rate increases. The potential greater proportion
of fee-for-service contracts with the Company's customers in 2001 compared to
prior years mitigates the potential adverse effects of price increases, although
no assurance can be given that the recent trend towards fee-for-service
arrangements will continue or that a substantial increase in drug costs or
utilization would not negatively affect the Company's overall profitability in
any period.
Generally, loss contracts arise only on capitated or other risk-based
contracts and primarily result from higher than expected pharmacy utilization
rates, higher than expected inflation in drug costs and the inability of the
Company to restrict its MCO clients' formularies to the extent anticipated by
the Company at the time contracted PBM services are implemented, thereby
resulting in higher than expected drug costs. At such time as management
estimates that a contract will sustain losses over its remaining contractual
life, a reserve is established for these estimated losses. There are currently
no loss contracts and management does not believe that there is an overall trend
towards losses on its existing capitated contracts.
In the first quarter of 2001, the Company commenced a stock repurchase
program pursuant to which the Company intends to repurchase up to $5 million of
the Company's Common Stock from time to time on the open market or in private
transactions. In February 2001, the Company repurchased 1,298,183 shares of
Common Stock for approximately $2.6 million at a price of $2.00 per share in
private transactions.
* * * *
11
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Interest rate risk represents the only market risk exposure applicable to
the Company. The Company's exposure to market risk for changes in interest rates
relates primarily to the Company's debt. The Company does not invest in or
otherwise use derivative financial instruments. The table below presents
principal cash flow amounts and related weighted average effective interest
rates by expected (contractual) maturity dates for the Company's financial
instruments subject to interest rate risk:
2001 2002 2003 2004 2005 Thereafter
----------------------------------------------------------------------
Long-term debt:
Variable rate instruments $ 109 $ - $ - $ - $ - $ -
Weighted average rate 7.43% 0.00% 0.00% 0.00% 0.00% 0.00%
In the table above, the weighted average interest rate for fixed and
variable rate financial instruments was computed utilizing the effective
interest rate for that instrument at March 31, 2001, and multiplying by the
percentage obtained by dividing the principal payments expected in that year
with respect to that instrument by the aggregate expected principal payments
with respect to all financial instruments within the same class of instrument.
At March 31, 2001, the carrying values of cash and cash equivalents,
accounts receivable, accounts payable, claims payable, payables to plan sponsors
and others, and debt approximate fair value due to their short-term nature.
Because management does not believe that its exposure to interest rate
market risk is material at this time, the Company has not developed or
implemented a strategy to manage this market risk through the use of derivative
financial instruments or otherwise. The Company will assess the significance of
interest rate market risk from time to time and will develop and implement
strategies to manage that risk as appropriate.
* * * *
12
PART II
OTHER INFORMATION
Item 1. Legal Proceedings
Since April 1999, the Company has been engaged in commercial arbitration
with Tennessee Health Partnership ("THP") over a number of commercial disputes
surrounding the parties' relationship. The Company had been disputing several
improper reductions of payments by THP that the Company believes were properly
due and owing to it. In addition, a dispute exists over whether or not certain
items should have been included under the Company's capitated arrangements with
THP. In 1999, the Company recorded a special charge of $3.3 million for
estimated future losses related to this dispute and another TennCare(R)
provider.
Early in 2001, the Company reached an agreement in principle with THP. The
Company paid THP $1.3 million in satisfaction of all claims between the parties.
The terms of the settlement were favorable to the Company and $1 million of
excess reserves were credited to income during the first quarter.
Item 2. Changes in Securities and Use of Proceeds
From August 14, 1996 through March 31, 2001, the $46.8 million net proceeds
from the Company's underwritten initial public offering of its Common Stock (the
"Offering"), affected pursuant to a Registration Statement assigned file number
333-05327 by the United States Securities and Exchange Commission (the
"Commission") and declared effective by the Commission on August 14, 1996, have
been applied in the following approximate amounts (in thousands):
Construction of plant, building and facilities............$ -
Purchase and installation of machinery and equipment......$ 15,092
Purchases of real estate..................................$ -
Acquisition of other businesses...........................$ 21,825
Repayment of indebtedness.................................$ -
Working capital...........................................$ 8,757
Temporary investments:
Marketable securities...............................$ -
Overnight cash deposits.............................$ 1,114
The Company expended a relatively insignificant portion of the Offering
proceeds on expansion of the Company's "preferred generics" business, which was
described more fully in the Offering prospectus, and the Company's Annual Report
on Form 10-K for the year ended December 31, 1996. At the time of the Offering
however, as disclosed in the prospectus, the Company intended to apply
approximately $18.6 million of Offering proceeds to fund such expansion. The
Company determined not to apply any material portion of the Offering proceeds to
fund the expansion of this business. The Company has used all of the net
proceeds from the Offering.
13
Item 4. Submission of Matters to a Vote of Security Holders
No matters were submitted to a vote of the Company's security holders during
the first quarter of fiscal year 2001.
Item 5. Other Information
None.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
Exhibit Number Description
- ----------------------------------------------------------------------------------------------------------------------------
10.74 Asset Purchase Agreement, dated April 4, 2001 among Continental Managed Pharmacy
Services Inc., Community Prescription Service, Inc., and its Stockholders.
(b) Reports on Form 8-K
None.
* * * *
14
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized, on May 14, 2001.
MIM CORPORATION
Date: May 14, 2001 /s/ Juliet A. Palmer
---------------------
Juliet A. Palmer
Vice President - Controller
(Principal Financial Officer)
15
Exhibit Index
(Exhibits being filed with this Quarterly Report on Form 10-Q)
Exhibit Number Description
- --------------------------------------------------------------------------------------------------------------------------
10.74 Asset Purchase Agreement, dated April 4, 2001 among Continental Managed Pharmacy
Services Inc., Community Prescription Service, Inc., and its Stockholders.
16